Evidence map›Paper›PMID 33961541›Full record

ReviewJournal of medical microbiology2021

Evaluation of metal-based antimicrobial compounds for the treatment of bacterial pathogens.

Andris Evans, Kevin A Kavanagh

Abstract readReview
In one paragraph

Review in Journal of medical microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed.

  1. Article
  2. Inhibition and disruption of bacterial biofilms by a bipyridine-ruthenium complex: a broad-spectrum in vitro study.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Role of AprA and pyocyanin fromMicrobiology (Reading, England) · 2025
    Article
  13. Review
  14. Antibiotic resistance and pathogenicity of Shiga-toxin-producingJournal of advanced veterinary and animal research · 2025
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Andris EvansSSPC Pharma Research Centre, Department of Biology, Maynooth University, Co. Kildare, Ireland.
Kevin A KavanaghSSPC Pharma Research Centre, Department of Biology, Maynooth University, Co. Kildare, Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance (AMR) is one of the greatest global health challenges of modern times and its prevalence is rising worldwide. AMR within bacteria reduces the efficacy of antibiotics and increases both the morbidity and the mortality associated with bacterial infections. Despite this growing risk, few antibiotics with a novel mode of action are being produced, leading to a lack of antibiotics that can effectively treat bacterial infections with AMR. Metals have a history of antibacterial use but upon the discovery of antibiotics, often became overlooked as antibacterial agents. Meanwhile, metal-based complexes have been used as treatments for other diseases, such as the gold-containing drug auranofin, used to treat rheumatoid arthritis. Metal-based antibacterial compounds have novel modes of action that provide an advantage for the treatment of bacterial infections with resistance to conventional antibiotics. In this review, the antibacterial activity, mode of action, and potential for systemic use of a number of metal-based antibacterial complexes are discussed. The current limitations of these compounds are highlighted to determine if metal-based agents are a potential solution for the treatment of bacterial infections, especially those resistant to conventional antibiotics.

Indexed as

Drug Resistance, BacterialAnti-Bacterial AgentsBacteriaMetalsAnti-Bacterial AgentsMetalsantibioticsbacterial pathogensinfectionmetal-based compoundsresistancetherapy

Identifiers

PMID33961541
PMCPMC8289199

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.